| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.suvenpharm.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 12,878.44 Cr. | |
| Earnings per share (EPS) | 14.23 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 35.54 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.15 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 46.39 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 10.91 | Calculated using Price: 505.90 |
| Dividend Yield | 0.20 | Period Ending 2020-03 |
| No. of Shares Subscribed | 25.46 Cr. | 254,564,957 Shares |
| FaceValue | 1 | |
| Company Profile | ||
|
Suven Pharmaceuticals Limited, a company incorporated in November 2018, has become Wholly Owned Subsidiary of Suven Life Sciences Limited, effective February 2019. Suven Life Sciences Limited, post the Board meeting on February 5, 2019, announced demerger of Suven Life Sciences Limited into: Suven Life Sciences Limited, the demerged entity, to continue innovative research focused on Central Nervous System (CNS) disorders to meet huge unmet global medical needs. Suven Pharmaceuticals Limited, the resultant entity, to continue the CRAMS business operations. The Scheme of Arrangement has since been approved by the National Company Law Tribunal (NCT), Hyderabad bench vide its order on 6th January 2020. Pursuant to the Scheme of Arrangement between Suven Life Sciences Limited (‘Demerged Company’), Suven Pharmaceuticals Limited (‘Resulting Company’) and their respective shareholders and creditors, duly approved by the National Company Law Tribunal (NCLT), Hyderabad Bench, vide its Order dated 06th January, 2020, the Demerged Undertaking (as defined in the Scheme) of the Demerged Company has been demerged from Suven Life Sciences Limited and the same has been transferred to and vested in Suven Pharmaceuticals Limited with effect from 1st October, 2018, being the Appointed Date fixed in the said Scheme of Arrangement. The Scheme, has become operative from the Appointed Date i.e., 1st October, 2018, but has become effective on 9th January, 2020 being the date on which certified copies of the Order of the NCLT, Hyderabad Bench sanctioning the Scheme was filed with the Registrar of Companies, Hyderabad, Telangana, both by the Demerged Company and Resulting Company. Business area of the company The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry. Business segments
|
||
Company Profile
Suven Pharmaceuticals Limited, a company incorporated in November 2018, has become Wholly Owned Subsidiary of Suven Life Sciences Limited, effective February 2019. Suven Life Sciences Limited, post the Board meeting on February 5, 2019, announced demerger of Suven Life Sciences Limited into: Suven Life Sciences Limited, the demerged entity, to continue innovative research focused on Central Nervous System (CNS) disorders to meet huge unmet global medical needs. Suven Pharmaceuticals Limited, the resultant entity, to continue the CRAMS business operations. The Scheme of Arrangement has since been approved by the National Company Law Tribunal (NCT), Hyderabad bench vide its order on 6th January 2020.
Pursuant to the Scheme of Arrangement between Suven Life Sciences Limited (‘Demerged Company’), Suven Pharmaceuticals Limited (‘Resulting Company’) and their respective shareholders and creditors, duly approved by the National Company Law Tribunal (NCLT), Hyderabad Bench, vide its Order dated 06th January, 2020, the Demerged Undertaking (as defined in the Scheme) of the Demerged Company has been demerged from Suven Life Sciences Limited and the same has been transferred to and vested in Suven Pharmaceuticals Limited with effect from 1st October, 2018, being the Appointed Date fixed in the said Scheme of Arrangement.
The Scheme, has become operative from the Appointed Date i.e., 1st October, 2018, but has become effective on 9th January, 2020 being the date on which certified copies of the Order of the NCLT, Hyderabad Bench sanctioning the Scheme was filed with the Registrar of Companies, Hyderabad, Telangana, both by the Demerged Company and Resulting Company.
Business area of the company
The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.
Business segments
| 1 Day |
|
+2.36% |
| 1 Week |
|
+3.55% |
| 1 Month |
|
+5.74% |
| 3 Month |
|
-4.14% |
| 6 Month |
|
+9.44% |
| 1 Year |
|
+63.80% |
| 2 Year |
|
|
| 5 Year |
|
| 2 years | 2019-03 | 2020-03 | |
| Return on Equity (%) | 18.92 | 37.80 | |
| Return on Capital Employed (%) | 23.87 | 44.55 | |
| Return on Assets (%) | 13.39 | 25.50 |
| Particulars | 2 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 590 | 845 | |
| Non Curr. Liab. | 35 | 128 | |
| Curr. Liab. | 191 | 320 | |
| Minority Int. | |||
| Equity & Liab. | 816 | 1,292 | |
| Non Curr. Assets | 393 | 781 | |
| Curr. Assets | 423 | 511 | |
| Misc. Exp. not W/O | |||
| Total Assets | 816 | 1,292 |
| Particulars | 2 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 378 | 834 | |
| Other Income | 1 | 18 | |
| Total Income | 378 | 852 | |
| Total Expenditure | -206 | -449 | |
| PBIDT | 172 | 403 | |
| Interest | -3 | -23 | |
| Depreciation | -12 | -24 | |
| Taxation | -49 | -88 | |
| Exceptional Items | |||
| PAT | 109 | 269 |
| Particulars | 2 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 50 | 416 | |
| Cash Fr. Inv. | -65 | -422 | |
| Cash Fr. Finan. | 26 | 6 | |
| Net Change | 11 | 1 | |
| Cash & Cash Eqvt | 11 | 12 |
|
Fri, 23 Jul 2021
Announcement under Regulation 30 (LODR)-Change in Directorate Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) We wish to inform you that Board of Directors of the Company at its meeting held today i.e. July 23 2021 based on the recommendation of the Nomination and Remuneration Committee appointed Dr. Vajja Sambasiva Rao (DIN: 09233939) as additional and an Independent Director effective from July 23 2021 for a period of 5 (five) years subject to the approval of the shareholders in the ensuing Annual General Meeting of the Company. The Board also approved investment of Rs 2.50 lakh (equivalent to 25% stake) by way of subscription in the new associate company - Rising Pharma Specialities Pvt. Ltd. under incorporation in India to take care of back office operations relating to Regulatory Accounting Information and Technology and other Logistic Services for Rising Pharma Holdings Inc. USA. |
||||||||||||||
|
Tue, 20 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
|
||||||||||||||
|
Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021 Suven Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here |
| Fri, 30 Jul 2021 |
High Delivery Percentage
|
Close Crossing Last Week High
|
Close Within 52 Week High Zone
|
| S Close Above Last Week High |
MFI Trending Up
|
Equities
M.F.
Sectors